Rationale: Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human skeletal muscle cells. Variations of CFTR dysfunction among patients with cystic fibrosis may be an important determinant of maximal exercise capacity in cystic fibrosis. Previous studies on the relationship between CFTR genotype and maximal exercise capacity are scarce and contradictory.
Cystic fibrosis (CF) is a disorder with autosomal recessive inheritance that ultimately leads to respiratory failure and premature death. The disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene coding for the CFTR protein that functions as an ion channel, mainly for chloride and bicarbonate (1) . CFTR mutations are grouped into different classes based on their effect on CFTR protein production, trafficking, function, and stability (1) . CFTR is expressed in cell membranes of epithelial cells. It can also be found at the level of the sarcoplasmic reticulum in airway smooth muscle (2) , human skeletal muscle cells (3, 4) , and myocardium (5) , but the precise physiological role of CFTR in these tissues is not fully understood (6) . Previous studies suggest intrinsic functional abnormalities in skeletal muscles lacking functional CFTR (3, 4) , possibly based on a disturbed calcium homeostasis in the muscle and increased systemic inflammation (3) . It is therefore plausible that dysfunctional CFTR in human skeletal muscle could be a factor contributing to peripheral muscle weakness (7, 8) and reduced exercise capacity (e.g., peak oxygen uptake [ _ VO 2peak ]) in CF (8, 9) .
Because _ VO 2peak is a predictor of mortality in CF (10) , knowledge of important correlates of aerobic performance may help to guide patient care. Few, predominantly small, studies have previously been done to investigate the relationships between CFTR genotype and _ VO 2peak in patients with CF (11) (12) (13) (14) , with equivocal and controversial results. Selvadurai and colleagues (12) found that children with CF carrying an F508del-CFTR gene mutation on one allele and a class I or class II CFTR mutation on the second allele had lower _ VO 2peak (approximately 30 to 45%) and peak anaerobic exercise capacity (approximately 10 to 17%) than children with a class III, IV, or V mutation on the second CFTR allele. However, this finding was based on univariate analysis of a relatively small sample size and thus did not control for relevant determinants of exercise capacity, such as nutritional status and chronic infection with Pseudomonas aeruginosa (8, 13, 15) , which could have influenced their study findings and interpretation.
The present study was designed to investigate factors associated with _ VO 2peak (primary endpoint) and maximum work rate (Watt max ; secondary endpoint) with a specific focus on CFTR genotype in a large international cohort of children and adults with CF. We aimed to compare maximal exercise capacity among patients with CFTR mutations that result in severely reduced function (combinations of classes I-III mutations) with that of patients with combinations of classes IV-V mutations characterized by some residual CFTR function at the cell surface (16) .
Methods Study Design and Patients
We invited members from the Exercise Working Group of the European Cystic Fibrosis Society to participate in the study. We also searched the PubMed database for publications on exercise testing in CF to identify clinical studies that included cardiopulmonary exercise testing (CPET). The CPET had to be performed on a cycle ergometer employing the Godfrey cycle protocol (17) or a modification thereof. Inclusion and exclusion criteria and detailed information on CPET can be found in the online supplement.
We collected data on anthropometric characteristics, CF-related comorbidities (e.g., exocrine pancreatic insufficiency, cystic fibrosis-related diabetes [CFRD], colonization with P. aeruginosa), pulmonary function, CPET-related data, and genetic data. Chronic P. aeruginosa infection was considered to be present when more than 50% of at least four sputum samples collected in the previous year were positive (18) . Spirometry was performed according to American Thoracic Society/European Respiratory Society standards (19) . We calculated percent predicted values for spirometry (20) , _ VO 2peak (21, 22) , Watt max (21, 23) , and peak heart rate (24), as well as z-scores for body mass index (BMI) based on World Health Organization criteria (25) . Percent body fat was calculated using sex-and agespecific prediction equations (26) , and lean body mass was derived from body fat and weight. For the final models, _ VO 2peak (primary endpoint) and Watt max (secondary endpoint) were expressed as percent predicted of reference values (22, 23) .
The classification of CFTR genotype (27, 28) was performed by a geneticist (S.G.) who was blinded to the exercise testing data. Details about the functional classification of CFTR alleles are shown in Table E1 in the online supplement. Study participants were grouped for the analysis of the primary endpoint ( _ VO 2peak percent predicted) in patients with both CFTR alleles in either class I, II, or III (corresponding to severely reduced CFTR function) and patients with at least one mutant allele in class IV or class V (corresponding to some residual CFTR function) (16) . In an exploratory analysis, we also compared maximal exercise capacity between patients with at least one copy of the F508del-CFTR mutation and categorized them into five groups on the basis of their second CFTR mutation class (11, 27) .
Ethical approval for this study was obtained from the cantonal ethical committee of Zurich, Switzerland (2015-0109). All centers obtained ethical approval (if required) for the use of their anonymized patient data according to national and local policies.
Statistical Analysis
Details on the statistical analyses can be found in the online supplement. We used analysis of variance, Kruskal-Wallis tests, and x 2 tests to compare variables between groups. We used mixed-effects models with a random intercept for study center to identify characteristics associated with _ VO 2peak and Watt max (percent predicted). Multilevel mixed-effects models with a random intercept for each study center were used to examine associations between CFTR genotype-based group and _ VO 2peak and Watt max (percent predicted). The models were a priori adjusted for the variables age, sex, BMI z-score, and forced expiratory volume in 1 second (FEV 1 ; percent predicted) because it is generally accepted that they have an influence on _ VO 2peak (9, 29, 30) . According to the results reported by van de Weert-van Leeuwen and colleagues (13) , chronic infection with P. aeruginosa is associated with decline in _ VO 2peak over time and therefore represents an important covariate in our model. To decide if the potential confounders CFRD or pancreatic insufficiency should be taken into account, the Akaike information criterion was used for model choice. However, the models did not improve when we added those variables, for which reason they were discarded. We also checked if interactions between CFTR genotypebased group and the other influential variables improved the models, which was not the case. To confirm our approach of defining the exercise capacity outcome variables as percent predicted values, we additionally performed linear mixed models using a multiplicative, allometric approach to account for potential effects of body size and pulmonary function on the relationship between CFTR genotype and _ VO 2peak (see online supplement).
Results
We contacted 32 centers in North America, Europe, Australia, and Asia by e-mail, 17 of which provided data for this study. Reasons for nonparticipation can be found in the online supplement. Included centers were in Canada (n = 3; 293 patients); the United States (n = 2; 110 patients); and one center each from Austria (n = 30 patients), Australia (n = 30 patients), France (n = 59 patients), Germany (n = 69 patients), Greece (n = 39 patients), Israel (n = 37 patients), Italy (n = 34 patients), the Netherlands (n = 93 patients), Spain (n = 51 patients), Serbia (n = 64 patients), Switzerland (n = 42 patients), and the United Kingdom (n = 39 patients). A flowchart of included patients is shown in Figure 1 , and patient characteristics are shown in Table 1 . Of 838 patients, 112 did not reach their maximal exercise level during the CPET and were excluded from further analyses. Criteria for a maximal effort during CPET are provided in the online supplement. These 112 patients were, on average, older, had lower FEV 1 , lower exercise capacity, and more CF-related comorbidities ( Figure 1 in the online supplement shows the relationship between FEV 1 and _ VO 2peak . Table 2 shows data for maximal exercise capacity, lung function, nutritional status, and CPET-related variables grouped by CFTR mutation class.
Predictors of Maximal Exercise Capacity in Patients with Cystic Fibrosis
In the univariate analysis adjusted for study center, we did not find any association of CFTR functional class (I-III vs. IV-V) with either _ VO 2peak percent predicted (b = 2.35; 95% CI, 21.27 to 6.35; P = 0.19) or Watt max percent predicted (b = 2.34; 95% CI, 21.90 to 6.58; P = 0.28). In contrast, age, FEV 1 percent predicted, BMI z-score, CFRD, and chronic P. aeruginosa infection were associated with _ VO 2peak and Watt max (expressed as percent predicted). Exocrine pancreatic insufficiency was associated only with Watt max (percent predicted). Forced vital capacity was not included in the final multilevel multivariate model, owing to a high collinearity with FEV 1 (R = 0.89; P = 0.001). We noted differences in _ VO 2peak and Watt max among study centers. Consequently, center was included as a random intercept in the multilevel mixed-effects models. In fully adjusted models, FEV 1 percent predicted (b = 0.41; 95% CI, 0.36 to 0.47; P , 0.001) and BMI z-score (b = 1.75; 95% CI, 0.76 to 2.74; P = 0.001) were significantly associated with _ VO 2peak (percent predicted). In the model for Watt max (percent predicted), FEV 1 percent predicted (b = 0.46; 95% CI, 0.40-0.52; P , 0.001) and BMI z-score (b = 1.27; 95% CI, 0.15-2.38; P = 0.03) remained the only significant predictors.
Associations of CFTR Functional Class and Maximal Exercise Capacity
The prevalence of CFRD, pancreatic insufficiency, and P. aeruginosa infection were higher for patients with only classes I-III CFTR mutations than for patients Subjects that met eligibility criteria N=838
Total study sample N=990
• N = 112 had no valid maximal CPET according to pre-specified criteria.
• N = 119 Missing information on CFTR mutations.
• N = 12 <8 years of age.
• N = 8 Missing CPET.
• N = 7 Treadmill exercise test.
• N = 6 Missing data (e.g. age, sex). 
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with at least one CFTR allele associated with residual function (class IV or class V). Univariate analysis revealed no differences in maximal exercise capacity (absolute and percent predicted _ VO 2peak and Watt max ) between the two groups (Table 3 ). In mixed-effects models, we did not detect an association between CFTR genotype functional class and either _ VO 2peak (percent predicted) (b = 20.95; 95% CI, 24.18 to 2.29; P = 0.57) or Watt max (b = 21.38; 95% CI, 25.04 to 2.27; P = 0.46). In these models, both lung function and nutritional status were associated with _ VO 2peak and Watt max (percent predicted) independent of CFTR function (Table 4) . These results were confirmed when allometric modeling was applied (Table E2 ) and when exercise capacity was expressed per kilogram of body weight or lean body mass (data not shown). Moreover, the results were similar when the 112 patients with nonmaximal CPETs were included in the analysis. In 835 and 831 patients, we found no association between CFTR genotype functional class and either _ VO 2peak (percent predicted) (b = 21.95; 95% CI, 25.28 to 1.39; P = 0.25) or Watt max (b = 22.42; 95% CI, 25.97 to 1.48; P = 0.24), respectively. In a subanalysis restricted to patients with preserved lung function (FEV 1 , >80% predicted) and nutritional status (BMI z-score, >50th percentile), we found no between-group differences in maximal exercise capacity in either univariate or adjusted analysis (Tables E3 and E4) . Furthermore, a subanalysis on patients with moderate to severe lung function impairment (FEV 1 , <60% predicted) did not show between-group differences in either _ VO 2peak or Watt max (percent predicted) (Tables E5 and E6 ).
Exercise Capacity among Patients with at Least One Copy of the

F508del-CFTR Mutation
In 653 patients who had at least one copy of the F508del-CFTR (class II) mutation grouped in five classes according to their second allele, no differences among CFTR genotype and either _ VO 2peak or Watt max were observed (absolute values or % predicted) (see Table E7 ). In mixed models, patients with one copy of a class V mutation had a significantly lower _ VO 2peak than patients with two copies of a class II mutation (b = 28.24%; 95% CI, 214.53 to 22.99; P = 0.003) (see Table E8 ).
Furthermore, Watt max values were lower for the group with one copy of a class V mutation (b = 27.59%; 95% CI, 214.21 to 20.95; P = 0.025). In addition, the same association was found for _ VO 2peak and Watt max (31) using allometric models (Table E9) .
Discussion
In this largest international multicenter study of exercise testing in patients with CF to date, we focused primarily on the relationship between CFTR genotype and predictors of maximal exercise capacity in patients with CF. We found that severity of CFTR genotype, using different CFTR categorizations, combinations, and analytic approaches, was not associated with maximal exercise capacity. In contrast, pulmonary function and nutritional status, expressed as BMI, were strongly associated with exercise capacity.
Our data do not support a relevant role of CFTR genotype on maximal exercise capacity in patients with CF. However, some theoretical considerations deserve further explanation to shed light on Respiratory exchange ratio data from two study centers were not available.
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potential underlying molecular mechanisms of the CFTR defect and its potential consequences on peripheral muscle function and exercise capacity. Recently, the expression of functional CFTR channels in human skeletal muscle was demonstrated (3, 4). Lamhonwah and colleagues (4) speculated that a dysfunction in sarcoplasmic reticulum CFTR channels might affect calcium release and thus impact the adenosine triphosphatemediated actin-myosin interaction that is essential for muscle contraction. Moreover, Divangahi and colleagues (3) suggested that excessive systemic inflammation initiates a process in which the abnormal vulnerability of CFTRdeficient muscle to proinflammatory mediators could play a key role in the development of skeletal muscle weakness observed in individuals with CF (7). Of note, these observations are based on animal experiments and have not yet been confirmed in humans. On the basis of the in vitro experiments suggesting that systemic inflammation in combination with CFTR dysfunction may impair skeletal muscle function, it is reasonable to speculate that potential detrimental effects of CFTR genotype on maximal exercise capacity would be detected only with high levels of inflammation. However, although the present study included patients with mildly impaired pulmonary function (mean 6 SD FEV 1 , 77.3 6 23% predicted), a subgroup analysis including only patients with moderate to severe lung disease (FEV 1 , <60% predicted) yielded similar results for the comparison between minimal function and residual function mutations (Tables E5   and E6 ). However, this subanalysis is limited by the small sample size of patients with residual function mutations and should be interpreted with caution. It remains to be shown in larger (ideally prospective) studies whether our findings are applicable to patients with more advanced disease and substantial inflammation.
Our main aim was to compare maximal exercise capacity between patients with CF carrying only minimal function CFTR mutations (classes I-III) and those with at least one residual function (class IV or V) CFTR mutation. In the primary analysis, our data showed no differences in maximal exercise capacity between groups in both unadjusted and adjusted analyses. These results were confirmed by the use of allometric models that were computed to exclude potential limitations of the prediction (32) . Regardless of the analytic approach, including adjustments for important confounders, we found robust evidence that CFTR genotype severity was not related to impaired maximal exercise capacity in patients with CF.
Our findings support previous studies showing that pulmonary function limitation and inadequate nutrition contribute to exercise intolerance in patients with CF (9, 13, 29, 30, 33, 34) . Nutritional status plays a critical role in the progression of lung disease. Compared with healthy subjects, patients with CF exhibit peripheral muscle weakness (35) that is associated with reduced aerobic exercise capacity (7, 8) . Thus, adequate nutrition and maintenance of BMI, and in particular muscle mass (35) , are important for preserving exercise tolerance in patients with CF. The strong impact of lung function and nutritional status could mask the effect of CFTR genotype on exercise capacity in patients with CF. Consequently, to exclusively study the role of CFTR genotype on exercise capacity, we performed a subanalysis restricted to patients with preserved lung function (FEV 1 , >80% predicted) and nutritional status (BMI z-score, >50th percentile), and the results remained qualitatively the same.
Our data are in contrast to a study by Selvadurai and colleagues (12) , who reported a relationship between the severity of CFTR functional impairment and reduced exercise capacity using univariate analysis in children with CF aged 8-17 years with at least one copy of the F508del-CFTR mutation. In univariate analysis, we noticed no differences between groups in either absolute or percent predicted values for _ VO 2peak or Watt max (Table E6 ). However, in the adjusted analysis, patients with one copy of a class V mutation had significantly lower exercise capacity (about 8% predicted for both _ VO 2peak and Watt max ) than patients homozygous for the F508del-CFTR mutation (Tables E7  and E8 ). Patients with one copy of a class V mutation did not differ in ethnicity and lung function but had better nutritional status compared with patients homozygous for the F508del-CFTR mutation. However, there was no evidence for ventilatory limitation (i.e., lower breathing reserve) during exercise in these patients, which may suggest that the lower exercise performance was reflective more of fitness level than of pulmonary status. Moreover, in mixed models, the presence of P. aeruginosa infection was significantly associated with a lower _ VO 2peak and Watt max (Table E8 ). This is supported by a study by van de Weert-van Leeuwen and colleagues (13) , who have previously shown that the presence of P. aeruginosa in adolescents with CF is a predictor of a steeper decline in _ VO 2peak over time, independent of age, nutritional status, pulmonary function, and immunoglobulin G levels. Nevertheless, relatively fewer patients with a group V mutation were colonized with P. aeruginosa than patients with solely CFTR class II mutations (reference group), despite a lower _ VO 2peak in the former than in the latter group. The differences between our study and the study by Selvadurai and colleagues (12) might be explained by the preserved lung function in the present cohort of patients and our rigorous adjustment for important clinical confounders in the statistical models. In addition, substantial CFTR genotype misclassification affecting different groups in the study by Selvadurai and colleagues (12) may contribute to the diverse findings. Finally, we can only speculate that lower habitual physical activity, a determinant of _ VO 2peak in CF (9), contributes to the reduced exercise capacity in patients with one copy of a class V mutation. The cohort of patients with a class IV or V CFTR mutation in our study might be a subgroup of patients that have been diagnosed at older ages (i.e., when their CF disease progressed and started to become symptomatic). Thus, later CF diagnosis and less focus clinically on exercise and physical activity may affect It is important to note that _ VO 2peak shows a large variation across the population, and available prediction equations have their limitations. Most of the equations that are used in CF research were established several decades ago, and mostly on the basis of small study samples that did not cover the whole age range of our population and/or did not consider both sexes (21, 22, 36) . We decided to use _ VO 2peak prediction equations published by Orenstein (22) because these equations were shown to be related to health-related quality of life (37), patient-reported health status (38) , and mortality (10) in patients with CF. In addition, we tested another frequently used prediction equation for _ VO 2peak (21) , and the results of all models were comparable to the prediction equation published by Orenstein (22) . However, when using equations from Jones and colleagues (21), we noticed significant associations between _ VO 2peak (and Watt max in percent predicted) with age and sex in the adjusted random effects models, which raises concern about the validity of these equations for this specific CF population.
This study has several limitations. First, we collected data from different international study centers. Thus, we cannot rule out differences in treatment strategies and treatment quality possibly affecting the health status of the patients, thereby introducing bias. Second, the groups classified according to CFTR classes were unevenly distributed, with a high number of patients in the group with the most common F508del-CFTR mutation (39, 40) compared with patients carrying a CFTR class I, III, IV, or V mutation. Despite the large sample size of 726 patients from 17 different CF centers worldwide, group sizes with CFTR classes I and III-V mutations were relatively small owing to the generally low prevalence of these gene mutations (41) . For these reasons, the exploratory analysis comparing exercise capacity among patients with at least one copy of the F508del-CFTR mutation should be interpreted with caution. Moreover, we were not able to consider all known confounders impacting exercise capacity, such as physical activity (9) , inflammatory markers, and other CF airway pathogens that were either not routinely assessed or not available for this retrospective analysis. Nevertheless, strong predictors of _ VO 2peak , such as pulmonary function (9, 13, 29, 30, 33) and nutritional status (34) , as well as proxy measures of inflammation (i.e., P. aeruginosa status), were included in our statistical analysis. In addition, our analysis was limited to maximal CPET outcomes. Additional measures such as _ VO 2 at the anaerobic threshold would have provided further insight into muscle (dys) function. Finally, we acknowledge the limitation of the retrospective study design and the collection of data over a large time period. However, it seems practically impossible to acquire such a large dataset on CPET variables within a prospective study that would overcome these limitations.
In summary, in our large, international cohort of children, adolescents, and adults with CF, we did not detect an association between CFTR genotype group and maximal exercise capacity. In this cohort, lower pulmonary function and worse nutritional status were associated with reduced exercise capacity. These findings underline the importance of preserving lung function and maintaining adequate nutrition to prevent exercise intolerance in patients with CF. n Author disclosures are available with the text of this article at www.atsjournals.org. Table 4 . Mixed models for association between patients with two CFTR mutations in class I, II, or III (group I-III) compared with patients with at least one mutation in class IV or V (group IV-V) Definition of abbreviations: CFTR = cystic fibrosis transmembrane conductance regulator; CI = confidence interval; FEV 1 = forced expiratory volume in 1 second; _ VO2 peak = peak oxygen consumption, Watt max = maximum work load. The categorical variable Pseudomonas aeruginosa is coded as 0 = no and 1 = yes. Sex is coded as 0 for females and 1 for males. CFTR groups are coded as 0 (classes I-III combined) and 1 (classes IV-V combined). _ VO2 peak and Watt max percent predicted values were calculated using reference equations from Orenstein (22) and Godfrey and colleagues (23), respectively.
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